1. Home
  2. GBIO vs ANTX Comparison

GBIO vs ANTX Comparison

Compare GBIO & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • ANTX
  • Stock Information
  • Founded
  • GBIO 2016
  • ANTX 2017
  • Country
  • GBIO United States
  • ANTX United States
  • Employees
  • GBIO N/A
  • ANTX N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • ANTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • GBIO Health Care
  • ANTX Health Care
  • Exchange
  • GBIO Nasdaq
  • ANTX Nasdaq
  • Market Cap
  • GBIO 29.2M
  • ANTX 33.2M
  • IPO Year
  • GBIO 2020
  • ANTX 2022
  • Fundamental
  • Price
  • GBIO $0.38
  • ANTX $1.07
  • Analyst Decision
  • GBIO Strong Buy
  • ANTX Buy
  • Analyst Count
  • GBIO 4
  • ANTX 2
  • Target Price
  • GBIO $7.33
  • ANTX $2.00
  • AVG Volume (30 Days)
  • GBIO 1.1M
  • ANTX 287.0K
  • Earning Date
  • GBIO 08-06-2025
  • ANTX 08-12-2025
  • Dividend Yield
  • GBIO N/A
  • ANTX N/A
  • EPS Growth
  • GBIO N/A
  • ANTX N/A
  • EPS
  • GBIO N/A
  • ANTX N/A
  • Revenue
  • GBIO $24,556,000.00
  • ANTX N/A
  • Revenue This Year
  • GBIO N/A
  • ANTX N/A
  • Revenue Next Year
  • GBIO N/A
  • ANTX N/A
  • P/E Ratio
  • GBIO N/A
  • ANTX N/A
  • Revenue Growth
  • GBIO 146.47
  • ANTX N/A
  • 52 Week Low
  • GBIO $0.30
  • ANTX $0.87
  • 52 Week High
  • GBIO $3.65
  • ANTX $3.07
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 49.21
  • ANTX 45.19
  • Support Level
  • GBIO $0.32
  • ANTX $1.07
  • Resistance Level
  • GBIO $0.36
  • ANTX $1.11
  • Average True Range (ATR)
  • GBIO 0.03
  • ANTX 0.04
  • MACD
  • GBIO 0.00
  • ANTX 0.00
  • Stochastic Oscillator
  • GBIO 64.67
  • ANTX 28.57

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About ANTX AN2 Therapeutics Inc.

AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.

Share on Social Networks: